Evidence map›Paper›PMID 39079848›Full record

ReviewArchivos de bronconeumologia2024

Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment.

Daniel Orive, Mirari Echepare, Franco Bernasconi-Bisio, Miguel Fernández Sanmamed, Antonio Pineda-Lucena, Carlos de la Calle-Arroyo, Frank Detterbeck, Rayjean J Hung, Mattias Johansson, Hilary A Robbins and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archivos de bronconeumologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel OriveSolid Tumors Program, CIMA-University of Navarra, Pamplona, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain; Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Mirari EchepareSolid Tumors Program, CIMA-University of Navarra, Pamplona, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain; Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Health Research Institute (IDISNA), Pamplona, Spain.
Franco Bernasconi-BisioMolecular Therapeutics Program, CIMA-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
Miguel Fernández SanmamedConsorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Program of Immunology and Immunotherapy, CIMA-University of Navarra, Pamplona, Spain; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Antonio Pineda-LucenaNavarra Health Research Institute (IDISNA), Pamplona, Spain; Molecular Therapeutics Program, CIMA-University of Navarra, Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
Carlos de la Calle-ArroyoInstituto de Ciencia de los Datos e Inteligencia Artificial (DATAI), Universidad de Navarra, Pamplona, Spain.
Frank DetterbeckDivision of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Rayjean J HungProsserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Mattias JohanssonInternational Agency for Research on Cancer, Lyon, France.
Hilary A RobbinsInternational Agency for Research on Cancer, Lyon, France.
Luis M SeijoCIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain; Pulmonary Department, Clínica Universidad de Navarra, Madrid, Spain.
Luis M MontuengaSolid Tumors Program, CIMA-University of Navarra, Pamplona, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain; Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Health Research Institute (IDISNA), Pamplona, Spain. Electronic address: lmontuenga@unav.es.
Karmele ValenciaSolid Tumors Program, CIMA-University of Navarra, Pamplona, Spain; Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Health Research Institute (IDISNA), Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain. Electronic address: kvalencia@unav.es.

Funding

Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, Rayjean J. Hung · 2017 to 2026
$23.7M
The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screeningR01CA262164 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI ROBBINS, HILARY A. · 2022 to 2025
$2.0M
NCI NIH HHS R01 CA262164NCI NIH HHS U19 CA203654World Health Organization 001
6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related deaths worldwide, mainly due to late diagnosis and the presence of metastases. Several countries around the world have adopted nation-wide LDCT-based lung cancer screening that will benefit patients, shifting the stage at diagnosis to earlier stages with more therapeutic options. Biomarkers can help to optimize the screening process, as well as refine the TNM stratification of lung cancer patients, providing information regarding prognostics and recommending management strategies. Moreover, novel adjuvant strategies will clearly benefit from previous knowledge of the potential aggressiveness and biological traits of a given early-stage surgically resected tumor. This review focuses on proteins as promising biomarkers in the context of lung cancer screening. Despite great efforts, there are still no successful examples of biomarkers in lung cancer that have reached the clinics to be used in early detection and early management. Thus, the field of biomarkers in early lung cancer remains an evident unmet need. A more specific objective of this review is to present an up-to-date technical assessment of the potential use of protein biomarkers in early lung cancer detection and management. We provide an overview regarding the benefits, challenges, pitfalls and constraints in the development process of protein-based biomarkers. Additionally, we examine how a number of emerging protein analytical technologies may contribute to the optimization of novel robust biomarkers for screening and effective management of lung cancer.

Indexed as

Biomarkers, TumorEarly Detection of CancerFeasibility StudiesLung NeoplasmsHumansNeoplasm ProteinsProteomicsBiomarkers, TumorNeoplasm ProteinsBiomarkersDiscoveryEarly stageHigh-plex technologiesLung cancerPrognosisProteinScreening

Identifiers

PMID39079848
PMCPMC12172408

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.